1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Aqua Pharmaceuticals Acquires Stiefel - Verdeso® Foam 0.05

M&A Deal Summary

Aqua Pharmaceuticals Acquires Stiefel - Verdeso® Foam 0.05

On June 5, 2013, Aqua Pharmaceuticals acquired medical products company Stiefel - Verdeso® Foam 0.05 from Stiefel Laboratories

Acquisition Highlights
  • This is Aqua Pharmaceuticals’ 1st transaction in the Medical Products sector.
  • This is Aqua Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2013-06-05
Target Stiefel - Verdeso® Foam 0.05
Sector Medical Products
Buyer(s) Aqua Pharmaceuticals
Sellers(s) Stiefel Laboratories
Deal Type Divestiture

Target

Stiefel - Verdeso® Foam 0.05

United States
Stiefel - Verdeso® (desonide) Foam 0.05% is a low-potency corticosteroid foam indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Aqua Pharmaceuticals

West Chester, Pennsylvania, United States
Category Company
Founded 2004
Sector Medical Products
DESCRIPTION

Aqua Pharmaceuticals LLC is a specialty dermatology pharmaceutical company focused on acquiring, developing and marketing under promoted, branded, pharmaceutical products. Utilizing its direct salesforce, Aqua promotes seven products throughout the United States including Monodox® (doxycycline monohydrate) capsules, an antibiotic used to treat acne; Cordran® lotion and cream, a topical corticosteroid used for the relief of inflammatory dermatoses; and Fluoroplex® (fluorouracil) cream, indicated for the treatment of actinic keratoses.

DEAL STATS #
Overall 1 of 1
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2013 M&A 1 of 1

Seller(S) 1

SELLER

Stiefel Laboratories

Research Triangle Park, North Carolina, United States
Category Company
Founded 1847
Sector Life Science
DESCRIPTION

Stiefel Laboratories, Inc. is enthusiastically committed to advancing dermatology and skin science around the world. The company’s deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel’s most valuable asset is its global network of nearly 3,500 driven associates.

DEAL STATS #
Overall 1 of 1
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2013 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-06-23 Barrier Therapeutics

Princeton, New Jersey, United States

Specialty pharmaceutical company focused on development and commercialization of dermatology drugs.

Buy -
Mergr

Solution for

Product

Company

Legal